Abbott Laboratories (ABT) Operating Leases (2019 - 2021)

Abbott Laboratories has disclosed Operating Leases across 3 years of filings, most recently posting $956.0 million for Q4 2021.

• Operating Leases for Q4 2021 came in at $956.0 million, up 5.99% year-over-year; the trailing twelve-month figure through Dec 2021 was $956.0 million (up 5.99% YoY), and the FY2021 annual result was $956.0 million, up 5.99% from the prior year.
• Operating Leases came in at $956.0 million for Q4 2021 at Abbott Laboratories, up from $902.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $956.0 million in Q4 2021 to a low of $755.0 million in Q4 2019.
• The 3-year median for Operating Leases is $902.0 million (2020), against an average of $871.0 million.
• Across the five-year window, Operating Leases gained 19.47% in 2020 and climbed 5.99% in 2021, its largest moves.
• Abbott Laboratories' Operating Leases stood at $755.0 million in 2019, then climbed by 19.47% to $902.0 million in 2020, then gained by 5.99% to $956.0 million in 2021.
• The last three Operating Leases figures came in at $956.0 million (Q4 2021), $902.0 million (Q4 2020), and $755.0 million (Q4 2019), per Business Quant data.